Reduction in antidrug antibody levels after switching to rituximab in patients with rheumatoid arthritis with prior infliximab or adalimumab secondary failure.
作者信息
Martínez Feito Ana, Plasencia-Rodríguez Chamaida, Navarro-Compán Victoria, Hernández-Breijo Borja, Nozal Pilar, Ángeles González María, Nuño Laura, Monjo Irene, Pascual-Salcedo Dora, Balsa Alejandro
机构信息
Immuno-Rheumatology group, La Paz University Hospital Institute for Health Research (IdiPAZ), Madrid, Spain; Immunology Unit, La Paz University Hospital, Madrid, Spain.
Immuno-Rheumatology group, La Paz University Hospital Institute for Health Research (IdiPAZ), Madrid, Spain; Rheumatology Department, La Paz University Hospital, Madrid, Spain.
出版信息
Semin Arthritis Rheum. 2020 Feb;50(1):E1-E2. doi: 10.1016/j.semarthrit.2019.06.021. Epub 2019 Jun 28.
Abstract
摘要
相似文献
1
Reduction in antidrug antibody levels after switching to rituximab in patients with rheumatoid arthritis with prior infliximab or adalimumab secondary failure.类风湿关节炎患者在先前使用英夫利昔单抗或阿达木单抗继发失败后改用利妥昔单抗后抗药物抗体水平降低。
Semin Arthritis Rheum. 2020 Feb;50(1):E1-E2. doi: 10.1016/j.semarthrit.2019.06.021. Epub 2019 Jun 28.
2
Effect of serum anti-tumour necrosis factor (TNF) drug trough concentrations and antidrug antibodies (ADAb) to further anti-TNF short-term effectiveness after switching in rheumatoid arthritis and axial spondyloarthritis.血清抗肿瘤坏死因子（TNF）药物谷浓度及抗药物抗体（ADAb）对类风湿关节炎和轴向脊柱关节炎换药后抗TNF短期疗效的影响。
Joint Bone Spine. 2016 Oct;83(5):595-7. doi: 10.1016/j.jbspin.2015.07.015. Epub 2016 Apr 8.
3
Incidence of Antidrug Antibodies in Rheumatoid Arthritis Patients From Argentina Treated With Adalimumab, Etanercept, or Infliximab in a Real-World Setting.阿根廷真实世界中阿达木单抗、依那西普和英夫利昔单抗治疗类风湿关节炎患者的抗药物抗体发生率。
J Clin Rheumatol. 2018 Jun;24(4):177-182. doi: 10.1097/RHU.0000000000000612.
4
Incidence and risk factors for adalimumab and infliximab anti-drug antibodies in rheumatoid arthritis: A European retrospective multicohort analysis.类风湿关节炎中阿达木单抗和英夫利昔单抗抗药物抗体的发生率和危险因素：一项欧洲回顾性多队列分析。
Semin Arthritis Rheum. 2019 Jun;48(6):967-975. doi: 10.1016/j.semarthrit.2018.10.006. Epub 2018 Oct 12.
5
Presence of anti-nuclear antibodies is a risk factor for the appearance of anti-drug antibodies during infliximab or adalimumab therapy in patients with rheumatoid arthritis.抗核抗体的存在是类风湿关节炎患者在接受英夫利昔单抗或阿达木单抗治疗时出现抗药物抗体的一个风险因素。
PLoS One. 2020 Dec 14;15(12):e0243729. doi: 10.1371/journal.pone.0243729. eCollection 2020.
6
7
Serum IL-33 level is associated with auto-antibodies but not with clinical response to biologic agents in rheumatoid arthritis.血清 IL-33 水平与自身抗体相关，但与类风湿关节炎生物制剂的临床反应无关。
Arthritis Res Ther. 2018 Jun 8;20(1):122. doi: 10.1186/s13075-018-1628-6.
8
An examination of the mechanisms involved in secondary clinical failure to adalimumab or etanercept in inflammatory arthropathies.对阿达木单抗或依那西普在炎性关节病中继发临床失败所涉及机制的研究。
J Clin Rheumatol. 2015 Apr;21(3):115-9. doi: 10.1097/RHU.0000000000000229.
9
Development of an ELISA-Based Competitive Binding Assay for the Analysis of Drug Concentration and Antidrug Antibody Levels in Patients Receiving Adalimumab or Infliximab.开发一种基于酶联免疫吸附测定的竞争性结合分析法，用于分析接受阿达木单抗或英夫利昔单抗治疗患者的药物浓度和抗药物抗体水平。
Ther Drug Monit. 2016 Feb;38(1):32-41. doi: 10.1097/FTD.0000000000000229.
10
The impact of anti-drug antibodies on drug concentrations and clinical outcomes in rheumatoid arthritis patients treated with adalimumab, etanercept, or infliximab: Results from a multinational, real-world clinical practice, non-interventional study.抗药抗体对接受阿达木单抗、依那西普或英夫利昔单抗治疗的类风湿关节炎患者药物浓度及临床结局的影响：一项跨国、真实世界临床实践、非干预性研究的结果
PLoS One. 2017 Apr 27;12(4):e0175207. doi: 10.1371/journal.pone.0175207. eCollection 2017.
Zotero 插件